Determination of favipiravir in human plasma using homogeneous liquid–liquid microextraction followed by HPLC/UV
Favipiravir is an antiviral drug that was recently approved for the management of COVID-19 infection. This work aimed to develop a new method, using sugaring-out induced homogeneous liquid–liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma. The optimum ex...
Gespeichert in:
| Veröffentlicht in: | Bioanalysis 2022-02, Vol.14 (4), p.205-216 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 216 |
|---|---|
| container_issue | 4 |
| container_start_page | 205 |
| container_title | Bioanalysis |
| container_volume | 14 |
| creator | Abdallah, Inas A Hammad, Sherin F Bedair, Alaa Elshafeey, Ahmed H Mansour, Fotouh R |
| description | Favipiravir is an antiviral drug that was recently approved for the management of COVID-19 infection.
This work aimed to develop a new method, using sugaring-out induced homogeneous liquid–liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma.
The optimum extraction conditions were attained using 500 μl of tetrahydrofuran as an extractant and 1400 mg of fructose as a phase-separating agent.
The developed method was validated according to the US FDA bioanalytical guidelines and was found linear in the range of 25-80,000 ng/ml with a correlation coefficient of 0.999.
These results showed that the developed method was simple, easy, valid and adequately sensitive for determination of favipiravir in plasma for bioequivalence studies. |
| doi_str_mv | 10.4155/bio-2021-0219 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_4155_bio_2021_0219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35001648</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-2e7ebe8ea03aafa3f4ac358baffe6aab512b4fc8955e1f5b9deb5a906c4da2413</originalsourceid><addsrcrecordid>eNp1kE1OwzAQRi0EolXpki3yBULtJG7jJSo_RaoEC8o2Gjvj1iiJi50A3XEHbshJSAmww9LYM9KbT9Yj5JSz85QLMVHWRTGLedSVPCBDPhOzaMqlPPzrMzYg4xCeWHeSOJOpPCaDRDDGp2k2JP4SG_SVraGxrqbOUAMvdmt9d3tqa7ppK6jptoRQAW2Drdd04yq3xhpdG2hpn1tbfL5_9A2trPYO3xoP-jvQuLJ0r1hQtaOL--V8sno8IUcGyoDjn3dEVtdXD_NFtLy7uZ1fLCOdpEkTxThDhRkCSwAMJCYFnYhMgTE4BVCCxyo1OpNCIDdCyQKVAMmmOi0gTnkyIlGf2_0oBI8m33pbgd_lnOV7fXmnL9_ry_f6Ov6s57etqrD4o39ldYDsAdM2rcegLdYa837qNqy2Nf4T_gVrBoO0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Determination of favipiravir in human plasma using homogeneous liquid–liquid microextraction followed by HPLC/UV</title><source>MEDLINE</source><source>PubMed Central</source><creator>Abdallah, Inas A ; Hammad, Sherin F ; Bedair, Alaa ; Elshafeey, Ahmed H ; Mansour, Fotouh R</creator><creatorcontrib>Abdallah, Inas A ; Hammad, Sherin F ; Bedair, Alaa ; Elshafeey, Ahmed H ; Mansour, Fotouh R</creatorcontrib><description>Favipiravir is an antiviral drug that was recently approved for the management of COVID-19 infection.
This work aimed to develop a new method, using sugaring-out induced homogeneous liquid–liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma.
The optimum extraction conditions were attained using 500 μl of tetrahydrofuran as an extractant and 1400 mg of fructose as a phase-separating agent.
The developed method was validated according to the US FDA bioanalytical guidelines and was found linear in the range of 25-80,000 ng/ml with a correlation coefficient of 0.999.
These results showed that the developed method was simple, easy, valid and adequately sensitive for determination of favipiravir in plasma for bioequivalence studies.</description><identifier>ISSN: 1757-6180</identifier><identifier>EISSN: 1757-6199</identifier><identifier>DOI: 10.4155/bio-2021-0219</identifier><identifier>PMID: 35001648</identifier><language>eng</language><publisher>England: Newlands Press Ltd</publisher><subject>Adult ; Amides - administration & dosage ; Amides - blood ; Antiviral Agents - administration & dosage ; Antiviral Agents - blood ; bioequivalence ; Chromatography, High Pressure Liquid - methods ; COVID-19 ; COVID-19 - drug therapy ; Drug Monitoring - methods ; favipiravir ; FDA ; Humans ; Limit of Detection ; Liquid Phase Microextraction - methods ; microextraction ; Pyrazines - administration & dosage ; Pyrazines - blood ; SARS-CoV-2 - drug effects ; sugaring-out</subject><ispartof>Bioanalysis, 2022-02, Vol.14 (4), p.205-216</ispartof><rights>2022 Newlands Press</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-2e7ebe8ea03aafa3f4ac358baffe6aab512b4fc8955e1f5b9deb5a906c4da2413</citedby><cites>FETCH-LOGICAL-c343t-2e7ebe8ea03aafa3f4ac358baffe6aab512b4fc8955e1f5b9deb5a906c4da2413</cites><orcidid>0000-0003-0847-4035</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35001648$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdallah, Inas A</creatorcontrib><creatorcontrib>Hammad, Sherin F</creatorcontrib><creatorcontrib>Bedair, Alaa</creatorcontrib><creatorcontrib>Elshafeey, Ahmed H</creatorcontrib><creatorcontrib>Mansour, Fotouh R</creatorcontrib><title>Determination of favipiravir in human plasma using homogeneous liquid–liquid microextraction followed by HPLC/UV</title><title>Bioanalysis</title><addtitle>Bioanalysis</addtitle><description>Favipiravir is an antiviral drug that was recently approved for the management of COVID-19 infection.
This work aimed to develop a new method, using sugaring-out induced homogeneous liquid–liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma.
The optimum extraction conditions were attained using 500 μl of tetrahydrofuran as an extractant and 1400 mg of fructose as a phase-separating agent.
The developed method was validated according to the US FDA bioanalytical guidelines and was found linear in the range of 25-80,000 ng/ml with a correlation coefficient of 0.999.
These results showed that the developed method was simple, easy, valid and adequately sensitive for determination of favipiravir in plasma for bioequivalence studies.</description><subject>Adult</subject><subject>Amides - administration & dosage</subject><subject>Amides - blood</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - blood</subject><subject>bioequivalence</subject><subject>Chromatography, High Pressure Liquid - methods</subject><subject>COVID-19</subject><subject>COVID-19 - drug therapy</subject><subject>Drug Monitoring - methods</subject><subject>favipiravir</subject><subject>FDA</subject><subject>Humans</subject><subject>Limit of Detection</subject><subject>Liquid Phase Microextraction - methods</subject><subject>microextraction</subject><subject>Pyrazines - administration & dosage</subject><subject>Pyrazines - blood</subject><subject>SARS-CoV-2 - drug effects</subject><subject>sugaring-out</subject><issn>1757-6180</issn><issn>1757-6199</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1OwzAQRi0EolXpki3yBULtJG7jJSo_RaoEC8o2Gjvj1iiJi50A3XEHbshJSAmww9LYM9KbT9Yj5JSz85QLMVHWRTGLedSVPCBDPhOzaMqlPPzrMzYg4xCeWHeSOJOpPCaDRDDGp2k2JP4SG_SVraGxrqbOUAMvdmt9d3tqa7ppK6jptoRQAW2Drdd04yq3xhpdG2hpn1tbfL5_9A2trPYO3xoP-jvQuLJ0r1hQtaOL--V8sno8IUcGyoDjn3dEVtdXD_NFtLy7uZ1fLCOdpEkTxThDhRkCSwAMJCYFnYhMgTE4BVCCxyo1OpNCIDdCyQKVAMmmOi0gTnkyIlGf2_0oBI8m33pbgd_lnOV7fXmnL9_ry_f6Ov6s57etqrD4o39ldYDsAdM2rcegLdYa837qNqy2Nf4T_gVrBoO0</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Abdallah, Inas A</creator><creator>Hammad, Sherin F</creator><creator>Bedair, Alaa</creator><creator>Elshafeey, Ahmed H</creator><creator>Mansour, Fotouh R</creator><general>Newlands Press Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-0847-4035</orcidid></search><sort><creationdate>20220201</creationdate><title>Determination of favipiravir in human plasma using homogeneous liquid–liquid microextraction followed by HPLC/UV</title><author>Abdallah, Inas A ; Hammad, Sherin F ; Bedair, Alaa ; Elshafeey, Ahmed H ; Mansour, Fotouh R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-2e7ebe8ea03aafa3f4ac358baffe6aab512b4fc8955e1f5b9deb5a906c4da2413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Amides - administration & dosage</topic><topic>Amides - blood</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - blood</topic><topic>bioequivalence</topic><topic>Chromatography, High Pressure Liquid - methods</topic><topic>COVID-19</topic><topic>COVID-19 - drug therapy</topic><topic>Drug Monitoring - methods</topic><topic>favipiravir</topic><topic>FDA</topic><topic>Humans</topic><topic>Limit of Detection</topic><topic>Liquid Phase Microextraction - methods</topic><topic>microextraction</topic><topic>Pyrazines - administration & dosage</topic><topic>Pyrazines - blood</topic><topic>SARS-CoV-2 - drug effects</topic><topic>sugaring-out</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdallah, Inas A</creatorcontrib><creatorcontrib>Hammad, Sherin F</creatorcontrib><creatorcontrib>Bedair, Alaa</creatorcontrib><creatorcontrib>Elshafeey, Ahmed H</creatorcontrib><creatorcontrib>Mansour, Fotouh R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Bioanalysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdallah, Inas A</au><au>Hammad, Sherin F</au><au>Bedair, Alaa</au><au>Elshafeey, Ahmed H</au><au>Mansour, Fotouh R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determination of favipiravir in human plasma using homogeneous liquid–liquid microextraction followed by HPLC/UV</atitle><jtitle>Bioanalysis</jtitle><addtitle>Bioanalysis</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>14</volume><issue>4</issue><spage>205</spage><epage>216</epage><pages>205-216</pages><issn>1757-6180</issn><eissn>1757-6199</eissn><abstract>Favipiravir is an antiviral drug that was recently approved for the management of COVID-19 infection.
This work aimed to develop a new method, using sugaring-out induced homogeneous liquid–liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma.
The optimum extraction conditions were attained using 500 μl of tetrahydrofuran as an extractant and 1400 mg of fructose as a phase-separating agent.
The developed method was validated according to the US FDA bioanalytical guidelines and was found linear in the range of 25-80,000 ng/ml with a correlation coefficient of 0.999.
These results showed that the developed method was simple, easy, valid and adequately sensitive for determination of favipiravir in plasma for bioequivalence studies.</abstract><cop>England</cop><pub>Newlands Press Ltd</pub><pmid>35001648</pmid><doi>10.4155/bio-2021-0219</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-0847-4035</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1757-6180 |
| ispartof | Bioanalysis, 2022-02, Vol.14 (4), p.205-216 |
| issn | 1757-6180 1757-6199 |
| language | eng |
| recordid | cdi_crossref_primary_10_4155_bio_2021_0219 |
| source | MEDLINE; PubMed Central |
| subjects | Adult Amides - administration & dosage Amides - blood Antiviral Agents - administration & dosage Antiviral Agents - blood bioequivalence Chromatography, High Pressure Liquid - methods COVID-19 COVID-19 - drug therapy Drug Monitoring - methods favipiravir FDA Humans Limit of Detection Liquid Phase Microextraction - methods microextraction Pyrazines - administration & dosage Pyrazines - blood SARS-CoV-2 - drug effects sugaring-out |
| title | Determination of favipiravir in human plasma using homogeneous liquid–liquid microextraction followed by HPLC/UV |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T16%3A56%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determination%20of%20favipiravir%20in%20human%20plasma%20using%20homogeneous%20liquid%E2%80%93liquid%20microextraction%20followed%20by%20HPLC/UV&rft.jtitle=Bioanalysis&rft.au=Abdallah,%20Inas%20A&rft.date=2022-02-01&rft.volume=14&rft.issue=4&rft.spage=205&rft.epage=216&rft.pages=205-216&rft.issn=1757-6180&rft.eissn=1757-6199&rft_id=info:doi/10.4155/bio-2021-0219&rft_dat=%3Cpubmed_cross%3E35001648%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35001648&rfr_iscdi=true |